Dilution or treatment | Mean survival time in days Β± SD (% survival) |
---|---|
1) RML titration series * | |
100 | 65.5 Β± 3.4 (0%) |
10-1 | 73.6 Β± 3.3 (0%) |
10-2 | 83.2 Β± 6.1 (0%) |
10-3 | 195.4 Β± 148.5 (22%) |
10-4 | 394.8 Β± 120.3 (78%) |
10-5 through 10-12 | 455 (100%) β study termination |
2) Treated RML | |
SPC-PL x 30 min | 67.1 Β± 2.6 (0%) |
SPC-PL x 90 min | 68.8 Β± 4.6 (0%) |
SPC-PL x 180 min | 68.5 Β± 2.8 (0%) |
SPC-PH x 30 min | 70.3 Β± 6.0 (0%) |
SPC-PH x 90 min | 71.0 Β± 5.1 (0%) |
SPC-PH x 180 min | 73.8 Β± 3.2 (0%) |
SPC-PL + SDS x 30 min | 93 Β± 9.7 (0%) |
SPC-PL + SDS x 90 min | 136.4 Β± 72.2 (10%) |
SPC-PL + SDS x 180 min | 178.7 Β± 92.4 (20%) |
SPC-PH + SDS x 30 min | 92.5 Β± 7.6 (0%) |
SPC-PH + SDS x 90 min | 86.4 Β± 6.9 (0%) |
SPC-PH + SDS x 180 min | 84.7 Β± 11.1 (0%) |
SDS x 30 min | 84.9 Β± 12.3 (0%) |
SDS x 90 min | 107.5 Β± 40.5 (0%) |
SDS x 180 min | 85.7 Β± 6.7 (0%) |